CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival

被引:5
|
作者
Pirosa, Maria Cristina [1 ,2 ]
Esposito, Fabiana [1 ]
Raia, Giorgio [3 ]
Chianca, Vito [3 ]
Cozzi, Andrea [3 ,4 ]
Ruinelli, Lorenzo [5 ,6 ]
Ceriani, Luca [2 ,3 ,7 ]
Zucca, Emanuele [1 ,2 ,7 ]
Del Grande, Filippo [3 ,7 ]
Rizzo, Stefania [3 ,7 ]
机构
[1] Ente Osped Cantonale EOC, Ist Oncol Svizzera Italiana IOSI, Via Osped 1, CH-6500 Bellinzona, Switzerland
[2] Inst Oncol Res IOR, Via Chiesa 5, Bellinzona, Switzerland
[3] Ente Osped Cantonale EOC, Ist Imaging Svizzera Italiana IIMSI, Clin Radiol, Via Tesserete 46, CH-6900 Lugano, Switzerland
[4] Policlin San Donato, Piazza E Malan 2, I-20097 Milan, Italy
[5] Ente Osped Cantonale, ICT Informat & Tecnol Comunicaz, CH-6500 Bellinzona, Switzerland
[6] Ente Osped Cantonale, CTU Clin Trial Unit, CH-6500 Bellinzona, Switzerland
[7] Univ Svizzera Italiana USI, Fac Sci Biomed, Via Buffi 13, CH-6900 Lugano, Switzerland
来源
RADIOLOGIA MEDICA | 2023年 / 128卷 / 12期
关键词
CT; Body composition; Bone mineral density; Non-hodgkin lymphoma; BONE-MINERAL DENSITY; ELDERLY-PATIENTS; CHEMOTHERAPY; OSTEOPOROSIS; RISK; CHOP;
D O I
10.1007/s11547-023-01723-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Primary purpose was to assess changes of bone mineral density (BMD) in diffuse large B cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP (like) chemotherapy regimen. Secondary purposes were to assess other body composition features changes and to assess the association of pre-therapy values and their changes over time with survival. Material and methods Patients selected underwent R-CHOP(like) regimen for DLBCL, and underwent PET-CT before and after treatment. Main clinical data collected included body mass index, date of last follow-up, date of progression, and date of death. From the low-dose CT images, BMD was assessed at the L1 level; the other body composition values, including muscle and fat distribution, were assessed at the L3 level by using a dedicated software. Descriptive statistics were reported as median and interquartile range, or frequencies and percentages. Statistical comparisons of body composition variables between pre- and post-treatment assessments were performed using the Wilcoxon matched pairs signed rank test. Non-normal distribution of variables was tested with the Shapiro-Wilk test. For qualitative variables, the Fisher exact test was used. Log rank test was used to compare survival between different subgroups of the study population defined by specific body composition cutoffs. The significance level was set at p < 0.05. Results Eighty-two patients were included. The mean follow-up was 37.5 +/- 21.4 months. A significant difference was found in mean BMD before and after R-CHOP(like) treatment (p < 0.0001). The same trend was observed for mean skeletal muscle area (SMA) (p = 0.004) and mean skeletal muscle index (SMI) (p = 0.006). No significant association was demonstrated between body composition variables, PFS and OS. Conclusion R-CHOP(like) treatment in DLBCL patients was associated with significant reduction of BMD, SMA and SMI.
引用
收藏
页码:1497 / 1507
页数:11
相关论文
共 50 条
  • [31] THE INFLUENCE OF TREATMENT FACILITY VOLUME ON SURVIVAL OF DIFFUSE LARGE B-CELL LYMPHOMA
    Go, R.
    Al-Hamadani, M.
    Shah, N.
    Habermann, E.
    HAEMATOLOGICA, 2015, 100 : 391 - 391
  • [32] Cell of Origin (COO) Association with High Body Mass Index (BMI) and Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Maignan, Kathleen
    Azzam, Shaked Peleg
    Adamson, Blythe
    Parrinello, Christina M.
    Carson, Kenneth R.
    BLOOD, 2019, 134
  • [33] Treatment of diffuse large B-cell lymphoma
    Gleissner, B.
    Zwick, C.
    Pfreundschuh, M.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2008, 133 (36) : 1785 - 1794
  • [34] Diffuse Large B Cell Lymphoma in Patients 80 Years and Older: Worse Survival After Treatment Without Increased Relapse Rates
    Keenan, Madison
    Diamond, Akiva
    Boughan, Kirsten
    Cooper, Brenda
    Gallogly, Molly
    Malek, Ehsan
    Metheny, Leland
    O'Brien, Timothy
    Otegbeye, Folashade
    Tomlinson, Benjamin
    de Lima, Marcos
    Caimi, Paolo F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 799 - 804
  • [35] Treatment of Diffuse Large B-Cell Lymphoma
    Miyazaki, Kana
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2016, 56 (02) : 79 - 88
  • [36] Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region
    Ahmed, Aseef H.
    Foster, Stephen
    Shields, Carol L.
    JAMA OPHTHALMOLOGY, 2017, 135 (10) : 1062 - 1068
  • [37] Comparison of survival outcomes of different treatment modalities for patients with primary splenic diffuse large B cell lymphoma
    Yonghao, Ouyang
    Yongyang, Wei
    Siqing, Yi
    Lihua, Chu
    Shuju, Tu
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1857 - 1865
  • [38] Comparison of survival outcomes of different treatment modalities for patients with primary splenic diffuse large B cell lymphoma
    Ouyang Yonghao
    Wei Yongyang
    Yi Siqing
    Chu Lihua
    Tu Shuju
    Annals of Hematology, 2023, 102 : 1857 - 1865
  • [39] Laterality and Survival Outcomes in Patients with Primary Testicular Diffuse Large B Cell Lymphoma
    Miao, Yi
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2019, 134
  • [40] Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma
    Han, Ying
    Yang, Jianliang
    Liu, Peng
    He, Xiaohui
    Zhang, Changgong
    Zhou, Shengyu
    Zhou, Liqiang
    Qin, Yan
    Song, Yongwen
    Sun, Yan
    Shi, Yuankai
    ONCOLOGIST, 2019, 24 (11): : E1251 - E1261